RHHBY
Roche Holdings AG ADR

3,653
Mkt Cap
$281.58B
Volume
1.51M
52W High
$60.85
52W Low
$35.07
PE Ratio
21.08
RHHBY Fundamentals
Price
$51.09
Prev Close
$50.59
Open
$50.75
50D MA
$51.26
Beta
0.38
Avg. Volume
2.17M
EPS (Annual)
$2.44
P/B
7.62
Rev/Employee
$656,820.44
$358,793.41
Loading...
Loading...
News
all
press releases
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Zacks·2d ago
News Placeholder
More News
News Placeholder
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
SRPT beats Q1 earnings and revenue estimates despite a sharp Elevidys sales drop, while maintaining its 2026 product revenue outlook.
Zacks·2d ago
News Placeholder
EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus
EXEL beats Q1 EPS estimates on lower costs and buybacks but misses on revenues; Cabometyx sales lag estimates as pipeline progress and new buybacks stay in focus.
Zacks·3d ago
News Placeholder
The Zacks Analyst Blog Highlights Microsoft, Bank of America, Roche and GSI Technology
Microsoft faces pressure from capacity constraints and competition, even as AI momentum and Azure growth drive demand beyond available supply.
Zacks·4d ago
News Placeholder
Top Analyst Reports for Microsoft, Bank of America & Roche
Microsoft faces Azure capacity limits and rising competition, but AI momentum and Copilot adoption fuel cloud growth and enterprise demand.
Zacks·4d ago
News Placeholder
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
ALNY beats Q1 earnings and revenue estimates as Amvuttra sales surge 187%, driving 96% revenue growth and offsetting declines in collaborator revenue and Onpattro sales.
Zacks·8d ago
News Placeholder
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
REGN tops Q1 estimates with strong Dupixent and Eylea HD growth, but the stock slips as Eylea sales plunge and competition intensifies.
Zacks·10d ago
News Placeholder
ABBV Beats on Q1 Earnings & Sales, Raises '26 EPS View
AbbVie tops Q1 estimates on strong Rinvoq and Skyrizi sales, lifts 2026 EPS outlook and gains premarket despite continued Humira and Imbruvica declines.
Zacks·10d ago
News Placeholder
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
Zacks·11d ago
News Placeholder
Novartis Q1 Earnings & Revenues Miss Estimates, Stock Down
NVS' Q1 miss reflects Entresto and Promacta generic hits, even as Kisqali, Pluvicto and Leqvio deliver strong growth and pipeline advances.
Zacks·11d ago
<
1
2
...
>

Latest RHHBY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.